pentobarbital will decrease the extent or result of aripiprazole by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
pentobarbital will lower the level or influence of theophylline by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
With therapeutic doses of TCAs, barbiturates improve metabolism and reduce blood concentrations of TCAs.
pentobarbital will decrease the extent or impact of capivasertib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Potent or average CYP3A inducers lower capivasertib exposure, which may decrease efficacy.
pentobarbital will lessen the extent or effect of bazedoxifene/conjugated estrogens by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
Reserve concomitant prescribing of such drugs in clients for whom other treatment method alternatives are inadequate. Restrict dosages and durations for the minimum amount required. Monitor carefully for indications of respiratory depression and sedation.
With therapeutic doses of TCAs, barbiturates improve metabolism and reduce blood concentrations of TCAs.
pentobarbital will decrease the extent or effect of methadone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
pentobarbital will lower the extent or result of zonisamide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unknown.
Reserve concomitant prescribing of these drugs in people for whom other treatment method choices are inadequate. Restrict dosages and durations on the minimum amount needed. Keep an eye on carefully for signs of respiratory despair and sedation.
Check Carefully (one)pentobarbital will minimize the extent or effect of fentanyl transdermal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Closely. Coadministration of fentanyl with CYP3A4 inducers could lead on to some lessen in fentanyl plasma concentrations, lack of efficacy or, maybe, enhancement of the withdrawal syndrome within a client who's got created Actual physical dependence to fentanyl. Right after stopping a CYP3A4 inducer, because the effects in the inducer drop, the fentanyl plasma concentration will enhance which could raise or extend each the therapeutic and adverse effects.
With therapeutic doses of TCAs, barbiturates here maximize metabolism and decrease blood concentrations of TCAs.
pentobarbital will lessen the level or outcome of nilotinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will reduce the level or result of tofacitinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. Loss of, or decreased reaction to tofacitinib may well occur when coadministered with strong CYP3A4 inducers